[Articles] Chlorhydrate de fenfluramine pour le traitement des crises dans le syndrome de Dravet: un essai randomisé, en double aveugle, contrôlé par placebo

[Articles] Chlorhydrate de fenfluramine pour le traitement des crises dans le syndrome de Dravet: un essai randomisé, en double aveugle, contrôlé par placebo

janvier 13, 2020 0 Par admin

Translating…

Summary

Background

Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy characterised by multiple types of frequent, disabling seizures. Fenfluramine has been reported to have antiseizure activity in observational studies of photosensitive epilepsy and Dravet syndrome. The aim of the present study was to assess the efficacy and safety of fenfluramine in patients with Dravet syndrome.

Methods

In this randomised, double-blind, placebo-controlled clinical trial, we enrolled children and young adults with Dravet syndrome. After a 6-week observation period to establish baseline monthly convulsive seizure frequency (MCSF; convulsive seizures were defined as hemiclonic, tonic, clonic, tonic-atonic, generalised tonic-clonic, and focal with clearly observable motor signs), patients were randomly assigned through an interactive web response system in a 1:1:1 ratio to placebo, fenfluramine 0·2 mg/kg per day, or fenfluramine 0·7 mg/kg per day, added to existing antiepileptic agents for 14 weeks. The primary outcome was the change in mean monthly frequency of convulsive seizures during the treatment period compared with baseline in the 0·7 mg/kg per day group versus placebo; 0·2 mg/kg per day versus placebo was assessed as a key secondary outcome. Analysis was by modified intention to treat. Safety analyses included all participants who received at least one dose of study medication. This trial is registered with

ClinicalTrials.gov

with two identical protocols

NCT02682927

and

NCT02826863

.

Findings

Between Jan 15, 2016, and Aug 14, 2017, we assessed 173 patients, of whom 119 patients (mean age 9·0 years, 64 [54%] male) were randomly assigned to receive either fenfluramine 0·2 mg/kg per day (39), fenfluramine 0·7 mg/kg per day (40) or placebo (40). During treatment, the median reduction in seizure frequency was 74·9% in the fenfluramine 0·7 mg/kg group (from median 20·7 seizures per 28 days to 4·7 seizures per 28 days), 42·3% in the fenfluramine 0·2 mg/kg group (from median 17·5 seizures per 28 days to 12·6 per 28 days), and 19·2% in the placebo group (from median 27·3 per 28 days to 22·0 per 28 days). The study met its primary efficacy endpoint, with fenfluramine 0·7 mg/kg per day showing a 62·3% greater reduction in mean MCSF compared with placebo (95% CI 47·7–72·8, p

Interpretation

In Dravet syndrome, fenfluramine provided significantly greater reduction in convulsive seizure frequency compared with placebo and was generally well tolerated, with no observed valvular heart disease or pulmonary arterial hypertension. Fenfluramine could be an important new treatment option for patients with Dravet syndrome.

Funding

Zogenix.

To read this article in full you will need to make a payment

References

  1. 1.
    • Dravet C

    The core Dravet syndrome phenotype.

    Epilepsia. 2011; 52: 3-9

  2. 2.
    • Lagae L
    • Brambilla I
    • Mingorance A
    • Gibson E
    • Battersby A

    Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey.

    Dev Med Child Neurol. 2018; 60: 63-72

  3. 3.
    • Aras LM
    • Isla J
    • Mingorance-Le Meur A

    The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome.

    Epilepsy Behav. 2015; 44: 104-109

  4. 4.
    • Gataullina S
    • Dulac O

    Is epilepsy the cause of comorbidities in Dravet syndrome?.

    Dev Med Child Neurol. 2018; 60: 8

  5. 5.
    • Cooper MS
    • McIntosh A
    • Crompton DE
    • et al.

    Mortality in Dravet syndrome.

    Epilepsy Res. 2016; 128: 43-47

  6. 6.
    • Skluzacek JV
    • Watts KP
    • Parsy O
    • Wical B
    • Camfield P

    Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief.

    Epilepsia. 2011; 52: 95-101

  7. 7.
    • Harden C
    • Tomson T
    • Gloss D
    • et al.

    Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

    Neurology. 2017; 88: 1674-1680

  8. 8.
    • Schoonjans A-N
    • Lagae L
    • Ceulemans B

    Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome.

    Ther Adv Neurol Disord. 2015; 8: 328-338

  9. 9.
    • Connolly HM
    • Crary JL
    • McGoon MD
    • et al.

    Valvular heart disease associated with fenfluramine-phentermine.

    N Engl J Med. 1997; 337: 581-588

  10. 10.
    • Abenhaim L
    • Moride Y
    • Brenot F
    • et al.

    Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

    N Engl J Med. 1996; 335: 609-616

  11. 11.
    • Ceulemans B
    • Boel M
    • Leyssens K
    • et al.

    Successful use of fenfluramine as an add-on treatment for Dravet syndrome.

    Epilepsia. 2012; 53: 1131-1139

  12. 12.
    • Ceulemans B
    • Schoonjans A-S
    • Marchau F
    • Paelinck B
    • Lagae L

    Five-year extended follow-up of 10 Dravet patients treated with fenfluramine.

    Epilepsia. 2016; 57: e129-e134

  13. 13.
    • Schoonjans A
    • Paelinck BP
    • Marchau F
    • et al.

    Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.

    Eur J Neurol. 2017; 24: 309-314

  14. 14.
    • Schoonjans AS
    • Marchau F
    • Paelinck BP
    • et al.

    Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population.

    Curr Med Res Opin. 2017; 33: 1773-1781

  15. 15.
    • Devinsky O
    • Cross JH
    • Wright S

    Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.

    N Engl J Med. 2017; 377: 699-700

  16. 16.
    • Gioia GA
    • Isquith PK
    • Retzlaff PD
    • Espy KA

    Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample.

    Child Neuropsychol. 2002; 8: 249-257

  17. 17.
    • Bowen R
    • Glicklich A
    • Khan M
    • et al.

    Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997.

    MMWR Morb Mortal Wkly Rep. 1997; 46: 1061-1066

  18. 18.
    • Ivy DD
    • Abman SH
    • Barst RJ
    • et al.

    Pediatric pulmonary hypertension.

    J Am Coll Cardiol. 2013; 62: D117-D126

  19. 19.
    • Sabaz M
    • Lawson JA
    • Cairns DR
    • et al.

    Validation of the quality of life in childhood epilepsy questionnaire in American epilepsy patients.

    Epilepsy Behav. 2003; 4: 680-691

  20. 20.
    • Varni JW
    • Seid M
    • Kurtin PS

    PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations.

    Med Care. 2001; 39: 800-812

  21. 21.
    • Chiron C
    • Marchand MC
    • Tran A
    • et al.

    Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.

    Lancet. 2000; 356: 1638-1642

  22. 22.
    • Canadian Agency for Drugs and Technologies in Health

    Stiripentol (Diacomit): for severe myoclonic epilepsy in infancey (Dravet syndrome).

  23. 23.
    • Dmitrienko A
    • Tamhame AC

    Gatekeeping procedures in clinical trials.

    in: Dmitrienko A Tamhame AC Bretz F Multiple testing problems in pharmaceutical statistics. Chapman and Hall/CRC, Boca Raton, FL2010

  24. 24.
    • Zoghbi WA
    • Adams D
    • Bonow RO
    • et al.

    Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance.

    J Am Soc Echocardiogr. 2017; 30: 303-371

  25. 25.
    • Campbell JD
    • Whittington MD
    • Kim CH
    • VanderVeen GR
    • Knupp KG
    • Gammaitoni A

    Assessing the impact of caring for a child with Dravet syndrome: results of a caregiver survey.

    Epilepsy Behav. 2018; 80: 152-156

  26. 26.
    • Whittington MD
    • Knupp KG
    • Vanderveen G
    • Kim C
    • Gammaitoni A
    • Campbell JD

    The direct and indirect costs of Dravet Syndrome.

    Epilepsy Behav. 2018; 80: 109-113

  27. 27.
    • Park SP
    • Kwon SH

    Cognitive effects of antiepileptic drugs.

    J Clin Neurol. 2008; 4: 99-106

  28. 28.
    • Brunklaus A
    • Zuberi SM

    Dravet syndrome—from epileptic encephalopathy to channelopathy.

    Epilepsia. 2014; 55: 979-984

  29. 29.
    • Catarino CB
    • Liu JY
    • Liagkouras I
    • et al.

    Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology.

    Brain. 2011; 134: 2982-3010

  30. 30.
    • Onakpoya IJ
    • Heneghan CJ
    • Aronson JK

    Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis.

    Crit Rev Toxicol. 2016; 46: 477-489

  31. 31.
    • Li R
    • Serdula MK
    • Williamson DF
    • Bowman BA
    • Graham DJ
    • Green L

    Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy.

    Int J Obes Relat Metab Disord. 1999; 23: 926-928

  32. 32.
    • Dahl CF
    • Allen MR
    • Urie PM
    • Hopkins PN

    Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals.

    BMC Med. 2008; 6: 34

  33. 33.
    • Rich S
    • Rubin L
    • Walker AM
    • Schneeweiss S
    • Abenhaim L

    Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.

    Chest. 2000; 117: 870-874

  34. 34.
    • Hopkins PN
    • Polukoff GI

    Risk of valvular heart disease associated with use of fenfluramine.

    BMC Cardiovasc Disord. 2003; 3: 5

  35. 35.
    • Jick H
    • Vasilakis C
    • Weinrauch LA
    • Meier CR
    • Jick SS
    • Derby LE

    A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.

    N Engl J Med. 1998; 339: 719-724

  36. 36.
    • Lancellotti P
    • Moura L
    • Pierard LA
    • et al.

    European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease).

    Eur J Echocardiogr. 2010; 11: 307-332

  37. 37.
    • Lancellotti P
    • Tribouilloy C
    • Hagendorff A
    • et al.

    European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease).

    Eur J Echocardiogr. 2010; 11: 223-244

  38. 38.

    Lai W, Pringsheim M, Farfel G, et al. Long-term cardiovascular safety of fenfluramine (Fintepla®) in the treatment of dravet syndrome: interim analysis of an open-label safety extension study annual meeting of the American Epilepsy Society. New Orleans, LA, USA; 2018.

  39. 39.
    • Webb RH
    • Gentles TL
    • Stirling JW
    • Lee M
    • O’Donnell C
    • Wilson NJ

    Valvular regurgitation using portable echocardiography in a healthy student population: implications for rheumatic heart disease screening.

    J Am Soc Echocardiogr. 2015; 28: 981-988

Article Info

Publication History

Published: December 17, 2019

Identification

DOI: https://doi.org/10.1016/S0140-6736(19)32500-0

Copyright

© 2019 Elsevier Ltd. All rights reserved.

ScienceDirect

Access this article on ScienceDirect

Linked Articles


Huile de CBD peut aider avec l’épilepsie. Visite HuileCBD.be


 
/>Lire la suite